



1 / 17



FIGO, International Federation of Gynecology and Obstetrics.

FIG. 1**Distribution of TCD31NV**

N= 1438

**FIG. 2**

2 / 17

Association of Treatment Effect with TTMPFS within Subgroups





FIG. 3



4 / 17

FOREST Plot: Association of Treatment Effect with TTMPFS within TCD31NV Subgroups




FIG. 5

5 / 17


CPP vs
CPB15+

Biomarker Low Subgroup

BM Level	PFS HR	CI	P-value	Bonferroni Correction
Low (Bottom 50%)	0.77	(0.58;1.02)	0.0655	>0.05
Low (Bottom 75%)	0.67	(0.53;0.84)	0.000711*	<0.05

Biomarker High Subgroup

BM Level	PFS HR	CI	P-value	Bonferroni Correction
High (Top 50%)	0.45	(0.34;0.6)	3.81e-08*	<0.05
High (Top 25%)	0.39	(0.26;0.58)	4.05e-06*	<0.05

**FIG. 6**

6 / 17

Association of Treatment Effect with TTMDIED within Subgroups




FIG. 7

7 / 17

FOREST Plot: Association of Treatment Effect with TTMDIED within TCD31NV Subgroups






FIG. 8





10 / 17

CPP vs
CPB15+

Biomarker Low Subgroup

BM Level	OS HR	CI	P-value	Bonferroni Correction
Low (Bottom 50%)	1.08	(0.83;1.4)	0.551	>0.05
Low (Bottom 75%)	1.03	(0.83;1.27)	0.791	>0.05

Biomarker High Subgroup

BM Level	OS HR	CI	P-value	Bonferroni Correction
High (Top 50%)	0.73	(0.56;0.94)	0.0155*	0.093
High (Top 25%)	0.56	(0.39;0.82)	0.00251*	0.01506 (<0.05)

FIG. 10




FIG. 11




FIG. 12




FIG. 13

14 / 17

CPP vs
CPB15+

PFS tVEGFA Cutoff Top 25%

BM Level	PFS HR	CI	P-value	Bonferroni Correction
High (Top 25%)	0.48	(0.32;0.71)	0.000282*	<0.005
Low (Bottom 75%)	0.67	(0.53;0.84)	0.000688*	<0.05

OS tVEGFA Cutoff Top 25%

BM Level	OS HR	CI	P-value	Bonferroni Correction
High (Top 25%)	0.64	(0.44;0.93)	0.018*	>0.05
High (Bottom 75%)	1	(0.81;1.23)	0.991	>0.05

FIG. 14




FIG. 15

16 / 17




FIG. 16




FIG. 17